Department of Joint and Trauma Surgery, Third Affiliated Hospital of Sun Yat-sen University, China.
Department of Orthopedics, First Affiliated Hospital of Anhui Medical University, China.
Biomed Res Int. 2020 Sep 21;2020:3178037. doi: 10.1155/2020/3178037. eCollection 2020.
Osteosarcoma is a highly malignant bone cancer which primarily occurs in children and young adults. Increasing evidence indicates that long noncoding RNAs (lncRNAs), which function as competing endogenous RNAs (ceRNAs) that sponge microRNAs (miRNAs) and messenger RNAs (mRNAs), play a pivotal role in the pathogenesis and progression of cancers. The regulatory mechanisms of lncRNA-mediated ceRNAs in osteosarcoma have not been fully elucidated. In this study, we identified differentially expressed lncRNAs, miRNAs, and mRNAs in osteosarcoma based on RNA microarray profiles in the Gene Expression Omnibus (GEO) database. A ceRNA network was constructed utilizing bioinformatic tools. Kaplan-Meier survival analysis showed that lncR-C3orf35 and HMGB1 were associated with poor prognosis of osteosarcoma patients. Furthermore, results of Gene Set Enrichment Analysis (GSEA) suggested that lncR-C3orf35 may be involved in cellular invasion, the Toll-like receptor signaling pathway, and immune cell infiltration in the tumor microenvironment. Further analysis showed that patients with osteosarcoma metastasis expressed higher levels of lncR-C3orf35 and HMGB1 compared to metastasis-free patients. Moreover, the metastasis-free survival rate of the high lncR-C3orf35/HMGB1 expression group was significantly lower than that of the low expression group. The ESTIMATE algorithm was used to calculate the immune score and stromal scores for each sample. High lncR-C3orf35 and HMGB1 levels were correlated with low immune scores. ImmuCellAI analysis revealed that a low proportion of macrophage infiltration was associated with high lncR-C3orf35 and HMGB1 expression. The differential expression of lncR-C3orf35, miR-142-3p, and HMGB1 was further verified by quantitative real-time PCR. This study indicates that lncR-C3orf35 could be considered as a novel potential biomarker and therapeutic target of osteosarcoma, which may contribute to a better understanding of ceRNA regulatory mechanisms.
骨肉瘤是一种高度恶性的骨癌,主要发生在儿童和青少年中。越来越多的证据表明,长链非编码 RNA(lncRNA)作为竞争性内源性 RNA(ceRNA),可吸收 microRNA(miRNA)和信使 RNA(mRNA),在癌症的发病机制和进展中发挥关键作用。lncRNA 介导的 ceRNA 在骨肉瘤中的调控机制尚未完全阐明。在这项研究中,我们根据 GEO 数据库中的 RNA 微阵列图谱鉴定了骨肉瘤中差异表达的 lncRNA、miRNA 和 mRNA。利用生物信息学工具构建了 ceRNA 网络。Kaplan-Meier 生存分析表明,lncR-C3orf35 和 HMGB1 与骨肉瘤患者的预后不良相关。此外,基因集富集分析(GSEA)的结果表明,lncR-C3orf35 可能参与细胞侵袭、Toll 样受体信号通路和肿瘤微环境中的免疫细胞浸润。进一步分析表明,骨肉瘤转移患者的 lncR-C3orf35 和 HMGB1 表达水平高于无转移患者。此外,高 lncR-C3orf35/HMGB1 表达组的无转移生存率明显低于低表达组。ESTIMATE 算法用于计算每个样本的免疫评分和基质评分。高 lncR-C3orf35 和 HMGB1 水平与低免疫评分相关。ImmuCellAI 分析表明,巨噬细胞浸润比例低与高 lncR-C3orf35 和 HMGB1 表达相关。lncR-C3orf35、miR-142-3p 和 HMGB1 的差异表达通过定量实时 PCR 进一步验证。本研究表明,lncR-C3orf35 可作为骨肉瘤的一种新的潜在生物标志物和治疗靶点,有助于更好地理解 ceRNA 调控机制。